<DOC>
	<DOCNO>NCT02099058</DOCNO>
	<brief_summary>This Phase 1/1b open-label study evaluate safety , pharmacokinetics ( PK ) , preliminary efficacy ABBV-399 subject advance solid tumor .</brief_summary>
	<brief_title>A Phase 1/1b Study With ABBV-399 , Antibody Drug Conjugate , Subjects With Advanced Solid Cancer Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Subject must advance solid tumor amenable surgical resection approve therapeutic option demonstrate clinical benefit base evidence gather study external source , Sponsor consultation Investigators , may decide limit specific tumor type . 2 . Subject Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . 3 . Subject must measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 . 4 . Subject one archive diagnostic formalinfixed paraffin embed ( FFPE ) tumor tissue confirm available analysis . 5 . Subject adequate bone marrow , renal , hepatic function . 6 . Women childbearing potential must negative serum pregnancy test within 14 day prior initiation treatment . 7 . Subjects combination therapy arm must eligible receive erlotinib , cetuximab , bevacizumab nivolumab per current prescribing information , discretion Investigator . 1 . Subject receive anticancer therapy include chemotherapy , radiation therapy , immunotherapy , biologic , investigational therapy within period 21 day herbal therapy within 7 day prior first dose ABBV399 . 2 . Subject know uncontrolled metastasis central nervous system ( CNS ) . Subjects brain metastasis eligible provide show clinical radiographic stable disease least 4 week definitive therapy use steroid least 4 week prior first dose ABBV399 . 3 . Subject unresolved adverse event &gt; = Grade 2 prior anticancer therapy , except alopecia anemia . 4 . Subject major surgery within 21 day prior first dose ABBV399 . 5 . Subject clinically significant uncontrolled condition ( ) . 6 . Subject history major immunologic reaction Immunoglobulin G ( IgG ) contain agent . 7 . Subjects enrol combination therapy phase must satisfy exclusion criterion also follow : Subjects may receive ABBV399 combination erlotinib , cetuximab , bevacizumab nivolumab medical condition opinion Investigator place subject unacceptably high risk toxicity combination . . Subjects may receive cetuximab Kras mutation . ii . Subjects may receive bevacizumab squamous Nonsmallcell lung carcinoma ( NSCLC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Cancer</keyword>
</DOC>